cytarabine
Cold Chain RequiredFDA Approved, EMA Approved
Description
Cytarabine is an antimetabolite chemotherapy agent that interferes with DNA synthesis. It is a standard component of induction and consolidation therapy for acute myeloid leukemia, including inherited forms. The drug is converted intracellularly to its active triphosphate form.
Indications & Therapeutic Use
acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia blast phase, meningeal leukemia
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
cytarabine
| Generic Name | cytarabine |
| Brands | 1 brand available |
| Active Ingredient | cytarabine |
| Drug Class | acute myeloid leukemia |
| Manufacturer | Pfizer |
| Dosage Forms | IV infusion, 20mg/mL, 100mg/mL; Intrathecal injection, 50mg/mL |
| Medical Code | L01BC01 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00002798 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes